BRIEF published on 11/19/2024 at 07:35, 2 days 6 hours ago AFYREN Receives Silver Medal from EcoVadis Sustainability EcoVadis CSR AFYREN Biobased Ingredients
PRESS RELEASE published on 11/19/2024 at 07:30, 2 days 6 hours ago Inside Information / Other news releases AFYREN awarded Silver Medal by EcoVadis with an improved score, recognized for sustainability efforts in greentech industry Sustainability EcoVadis Silver Medal GreenTech AFYREN
BRIEF published on 09/30/2024 at 07:35, 1 month 21 days ago AFYREN publishes its 2024 half-year financial results Financial Results Strategic Partnerships Treasury Sustainable Production AFYREN NEOXY
PRESS RELEASE published on 09/30/2024 at 07:30, 1 month 21 days ago Inside Information / News release on accounts, results AFYREN announces its 2024 half-year financial results, highlighting adjustments needed for continuous production of AFYREN NEOXY products. Solid financial base supports operations with €43 million in cash as of June 2024 Cash Position Financial Base AFYREN Continuous Production 2024 Half-year Financial Results
BRIEF published on 08/29/2024 at 07:50, 2 months 23 days ago AFYREN Signs Multi-Year Contract with US Nutraceutical Manufacturer Sustainability GreenTech Nutraceuticals AFYREN Bio-based Ingredients
PRESS RELEASE published on 08/29/2024 at 07:45, 2 months 23 days ago Inside Information / Other news releases AFYREN signs multi-year commercial contract with US nutraceutical company for bio-based acids, tapping into fast-growing market. Contract underscores focus on natural, sustainable solutions for health & well-being Sustainable Solutions Nutraceuticals AFYREN Commercial Contract Bio-based Acids
BRIEF published on 07/09/2024 at 07:50, 4 months 12 days ago AFYREN reaches 2 million hours of laboratory fermentation Innovation Biotechnology Biomass Fermentation AFYREN
PRESS RELEASE published on 07/09/2024 at 07:45, 4 months 12 days ago Inside Information / Other news releases AFYREN's fermentation lab reaches 2-million-hour mark as it identifies new raw materials for industrial expansion. Company utilizes biomimetic process, partnerships, and circular value chains to produce bio-based ingredients Raw Materials AFYREN Fermentation Lab Biomimetic Process Industrial Expansion
BRIEF published on 06/21/2024 at 17:55, 4 months 29 days ago AFYREN Shareholders Approve All Resolutions at 2024 General Meeting Board Of Directors Shareholders General Meeting Resolutions AFYREN
PRESS RELEASE published on 06/21/2024 at 17:50, 4 months 29 days ago Inside Information / Other news releases AFYREN shareholders represented 78% of the Company’s capital at General Meeting approving resolutions. Details available on AFYREN Investors website Shareholders General Meeting Resolutions AFYREN Bio-based Ingredients
Published on 11/21/2024 at 14:15, 11 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 26 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 26 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 26 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 10 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 11 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 51 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 28 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 6 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 41 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 41 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
